Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05462951 · ClinicalTrials.gov registry record

Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer

A clinical trial of Uterine Cervix Cancer, sponsored by Denise Fabian.

Active
Registry status
19
Enrollment target
1
Study location

NCT05462951: Active study of Uterine Cervix Cancer, sponsored by Denise Fabian.

NCT05462951 is a study of Uterine Cervix Cancer that is active but no longer recruiting, run by Denise Fabian. The registered enrollment target is 19 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05462951, a study of Uterine Cervix Cancer, is active but no longer recruiting, sponsored by Denise Fabian.

ACTIVE NOT RECRUITING
Registry status
19 participants
Enrollment target
1
Study location

Study Summary

This is a phase 0 clinical trial of molecular biomarkers in women with uterine cervix cancer. Women receive standard-of-care radiochemotherapy followed by brachytherapy. Blood samples are obtained to detect circulating levels of deoxyribonucleotides, human papillomavirus DNA, and circulating tumor cells.

Primary Outcome

deoxyribonucleotide levels

Conditions Studied

Interventions

  • RADIATION Standard

Study Locations (1)

Kentucky

  • Markey Cancer Center - Lexington

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2023-01-03
Est. Completion 2026-06-01
Denise Fabian

3 total trials

What the registry record for NCT05462951 still lists

NCT05462951 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.

The record links to 1 condition, with Uterine Cervix Cancer appearing as the primary indexed condition, and to 1 intervention - of which Standard is the first listed.

NCT05462951 reports a single indexed study location in Kentucky.

Frequently Asked Questions

What is clinical trial NCT05462951 about?

NCT05462951 is a clinical study titled "Clinical Trial of Molecular Biomarkers in Women With Uterine Cervix Cancer". This is a phase 0 clinical trial of molecular biomarkers in women with uterine cervix cancer. Women receive standard-of-care radiochemotherapy followed by brachytherapy. Blood samples are obtained to detect circulating levels of deoxyribonucleotides, human papillomavirus DNA, and circulating tumor c...

What is the current status of trial NCT05462951?

This trial is currently active not recruiting. The enrollment target is 19 participants. The study started on 2023-01-03. Estimated completion is 2026-06-01.

What conditions does trial NCT05462951 study?

This clinical trial studies the following conditions: Uterine Cervix Cancer.

What interventions are being tested in trial NCT05462951?

The interventions under investigation include: Standard (RADIATION).

Who is sponsoring clinical trial NCT05462951?

This trial is sponsored by Denise Fabian, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05462951 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Uterine Cervix Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05607407 · 19 participants · Phase 2

    Methimazole in Patients With Progressive Glioblastoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05462951, the US trial registry maintained by the National Library of Medicine. NCT05462951 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.